You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
通化東寶(600867.SH):人胰島素注射液等5個產品擬中標第六批全國藥品集採
格隆匯 11-26 16:15

格隆匯11月26日丨通化東寶(600867.SH)公佈,2021年11月26日,公司參加了國家組織藥品集中採購和使用聯合採購辦公室組織的第六批全國藥品集中採購(胰島素專項)的投標工作。公司人胰島素注射液、精蛋白人胰島素注射液、精蛋白人胰島素混合注射液、甘精胰島素注射液、門冬胰島素注射液多個規格產品擬中標本次集中採購。

公司所有胰島素產品均參與本次胰島素集採競標工作,且全線產品以B類擬中標。公司上述擬中標產品2020年度合計銷售額為233,804萬元,佔公司2020年度營業收入比例為80.84%,2021年前三季度合計銷售額為205,103萬元,佔公司2021年前三季度營業收入比例為83.54%。

本次集中採購是國家組織的第六批全國藥品集中採購(胰島素專項),採購週期中,醫療機構將優先使用本次藥品集中採購中選藥品,並確保完成約定採購量。本次公司擬中選產品價格與原價格相比有一定幅度下降,但有約定的採購基礎量的保障。同時上述B類中標產品還將獲得D類中選產品首年採購需求量的80%的增量。此外,公司仍可以由於醫療機構的選擇獲得集採約定採購量之外的其他用量。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account